Citigroup issued a buy rating and price target for Neurocrine Biosciences, with MarketBeat reporting stock average rating.
1 report, 1 independent
Updated Jul 1
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Citigroup issued a buy rating and price target for Neurocrine Biosciences, with MarketBeat reporting stock average rating.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Citigroup
American investment bank and financial services corporation
-
Neurocrine Biosciences
American biopharmaceutical company
Nothing else this week.
-
MarketBeat
American personal finance blog
Related events
- Anixa Biosciences disclosed an insider purchase via SEC filing, coinciding with MarketBeat price target changes and a buy rating restatement from Citigroup.
- Citigroup provided a rating, Truist Financial boosted the price target, and MarketBeat aggregated consensus data for AMN stock.
- MarketBeat reported consensus ratings, Geode Capital Management raised its stake, Citigroup reissued a buy rating, and Benchmark restated a speculative buy rating regarding Intensity Therapeutics.
- MarketBeat reports consensus rating, Citigroup restates a market outperform rating, and Jefferies Financial Group sets a $28.00 target price for Four Corners Property Trust.
- Citigroup and Truist Financial issued buy ratings and increased price targets for Cisco.